GlassScriptPhysician profile
Michael L Kasper
NPI 1215016225
$2,745.18
in general payments reported to CMS, 2019-2025
19 companies · $350 in 2025
The $350 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $345 · 2021: $520 · 2022: $639 · 2023: $401 · 2024: $295 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $360.09 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $336.60 | 2020-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tris Pharma INC | $329.68 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $274.19 | 2021-2025 | Azstarys |
| Cranial Technologies, INC | $252.65 | 2019-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $196.55 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $191.97 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $188.13 | 2023-2024 | Bexsero, Rotarix, Pediarix |
| Adlon Therapeutics L.P. | $159.79 | 2019-2021 | |
| Pfizer INC. | $138.57 | 2019-2023 | |
| Sanofi Pasteur INC. | $81.18 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $77.48 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $42.22 | 2019-2021 | |
| Kaleo, INC. | $27.81 | 2022 | |
| Dermira, INC. | $24.57 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.48 | 2020 | |
| Shire North American Group INC | $18.00 | 2019 | |
| Noven Therapeutics, LLC | $15.42 | 2025 | Xelstrym |
| Allergan, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.